Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Influenza

Free Subscription 19.05.2025 1 Biochem Biophys Res Commun 1 J Gen Virol 1 J Immunol 1 J Infect Dis 1 J Virol 2 J Virol Methods 1 PLoS Comput Biol 27 PLoS One 41 Vaccine 2 Virology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Biochem Biophys Res Commun

1. PERFILOVA KV, Matyuta IO, Minyaev ME, Boyko KM, et al
   High-resolution structure reveals enhanced 14-3-3 binding by a mutant SARS-CoV-2 nucleoprotein variant with improved replicative fitness.
   Biochem Biophys Res Commun. 2025;767:151915.
   PubMed         Abstract available
   
   

   
   J Gen Virol

2. AHMED MN, Abu Habib US, Abdallah AM, Emara MM, et al
   The impact of pre-existing immunity on the emergence of within-host immune-escape mutations in Omicron lineages.
   J Gen Virol. 2025;106:002108.
   PubMed         Abstract available
   
   

   
   J Immunol

3. NOURI HR, Schaunaman N, Kraft M, Numata M, et al
   Tollip deficiency enhances mitophagy and reduces STING activation in influenza A virus-infected mice.
   J Immunol. 2025 May 16:vkaf058. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Infect Dis

4. ZHU S, Quint J, Leon T, Sun M, et al
   Estimating Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Using Linked Public Health Information Systems, California, 2023-2024 Season.
   J Infect Dis. 2025 May 13:jiaf248. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

5. KOUTSAKOS M, Reynaldi A, Aban M, Barr IG, et al
   Binding antibody titers against the hemagglutinin and neuraminidase correlate with protection against medically attended influenza A and B disease.
   J Virol. 2025 May 13:e0039125. doi: 10.1128/jvi.00391.
   PubMed         Abstract available
   
   

   
   J Virol Methods

6. WU JS, Kan JY, Chang YS, Phuong Le UN, et al
   Developing Zika virus-transduced hACE2 expression models for severe acute respiratory syndrome coronavirus 2 infection in vitro and in vivo.
   J Virol Methods. 2025 Apr 14:115166. doi: 10.1016/j.jviromet.2025.115166.
   PubMed         Abstract available
   
   
7. PUGLIA I, Caporale M, Di Teodoro G, Spedicato M, et al
   Optimization of an infectious subgenomic amplicons reverse genetics protocol for the rescue of synthetic coronaviruses.
   J Virol Methods. 2025;336:115152.
   PubMed         Abstract available
   
   

   
   PLoS Comput Biol

8. FERRAZ MVF, Adan WCS, Lima TE, Santos AJC, et al
   Design of nanobody targeting SARS-CoV-2 spike glycoprotein using CDR-grafting assisted by molecular simulation and machine learning.
   PLoS Comput Biol. 2025;21:e1012921.
   PubMed         Abstract available
   
   

   
   PLoS One

9. STEPHENS CR, Gutierrez JP
   A conceptual and computational framework for modeling the complex, adaptive dynamics of epidemics: The case of the SARS-CoV-2 pandemic in Mexico.
   PLoS One. 2025;20:e0323473.
   PubMed         Abstract available
   
   
10. KIM SH, Jung M
    Disentangling behavioral determinants of seasonal influenza vaccination in post-corona era: An integrated model approach.
    PLoS One. 2025;20:e0323184.
    PubMed         Abstract available
    
    
11. SZNAJDER KK, Legro RS, Teti D, Mackeen AD, et al
    Maternal and infant health during the COVID-19 pandemic - A Pennsylvania Study Protocol.
    PLoS One. 2025;20:e0323891.
    PubMed         Abstract available
    
    
12. GAUFFIN K, Ostergren O, Cederstrom A
    The global response to the pandemic: An empirical cluster analysis of policies targeting COVID-19.
    PLoS One. 2025;20:e0322692.
    PubMed         Abstract available
    
    
13. THAKKAR V, Silverman GM, Kc A, Ingraham NE, et al
    A comparative analysis of large language models versus traditional information extraction methods for real-world evidence of patient symptomatology in acute and post-acute sequelae of SARS-CoV-2.
    PLoS One. 2025;20:e0323535.
    PubMed         Abstract available
    
    
14. LAWRENCE MR, Arnetz JE, Counts SE, Ahmed A, et al
    Self-reported health, neuropsychological tests and biomarkers in fully recovered COVID-19 patients vs patients with post-COVID cognitive symptoms: A pilot study.
    PLoS One. 2025;20:e0315486.
    PubMed         Abstract available
    
    
15. SANCHEZ CODEZ MI, Benavente Fernandez I, Moyer K, Leber AL, et al
    The differential burden of acute rhinovirus infections in children with underlying conditions.
    PLoS One. 2025;20:e0313237.
    PubMed         Abstract available
    
    
16. JACOBS M, Haelermans C, Meeter M
    Effective remediation programs for vulnerable students to overcome learning loss.
    PLoS One. 2025;20:e0323352.
    PubMed         Abstract available
    
    
17. BUSZKIEWICZ JH, Tseng AS, Dai J, Ismach A, et al
    Association between early-pandemic food assistance use and subsequent food security trajectories among households in Washington State during the first three years of the COVID-19 pandemic.
    PLoS One. 2025;20:e0321585.
    PubMed         Abstract available
    
    
18. KAWASE A, Fukushige M
    Expectations regarding the effectiveness of mask-wearing and pandemic fatigue: The experience in Japan.
    PLoS One. 2025;20:e0321402.
    PubMed         Abstract available
    
    
19. FAQIHI F, Perri R, Chien J, Cho JG, et al
    Universal health care delivery mitigates socioeconomic-related risk for adverse outcomes in hospitalised patients: Lessons from the COVID-19 pandemic in Australia.
    PLoS One. 2025;20:e0322780.
    PubMed         Abstract available
    
    
20. XIA Z, Meng J, Wang X, Liu P, et al
    Efficacy of BCG vaccination against COVID-19 in health care workers and non-health care workers: A meta-analysis of randomized controlled trials.
    PLoS One. 2025;20:e0321511.
    PubMed         Abstract available
    
    
21. SINGH-VERDEFLOR KD, Kelly MM, DeMuri GP, Warner G, et al
    Differences in COVID-19 testing perceptions among caregivers of children with medical complexity by rurality.
    PLoS One. 2025;20:e0323651.
    PubMed         Abstract available
    
    
22. KANERVA M, Rautava K, Kurvinen T, Marttila H, et al
    Economic impact and disease burden of COVID-19 in a tertiary care hospital: A three-year analysis.
    PLoS One. 2025;20:e0323200.
    PubMed         Abstract available
    
    
23. ABRAMOVA D, Haase PM, Just AM, Frank S, et al
    Impact of prior SARS-CoV-2 infection on perioperative cardiac, pulmonary and neurocognitive complications in older patients: Study protocol for an observative case control study.
    PLoS One. 2025;20:e0323599.
    PubMed         Abstract available
    
    
24. BEISSAT K, Lattard V, Picard-Meyer E, Fafournoux A, et al
    Infectious potential and circulation of SARS-CoV-2 in wild rats.
    PLoS One. 2025;20:e0316882.
    PubMed         Abstract available
    
    
25. NKHATA A, Shi X, Zhang Y, Chen H, et al
    Construction and application of SARS-CoV-2 protein ontology (CoVPO).
    PLoS One. 2025;20:e0317589.
    PubMed         Abstract available
    
    
26. LIN YE, Chien LY, Hu ML
    The relationships among nurses' spiritual health, sleep quality, and stress and the factors influencing stress during the late global COVID-19 pandemic: A cross- sectional study.
    PLoS One. 2025;20:e0323164.
    PubMed         Abstract available
    
    
27. YANG MJ, Gaulin M, Seegert N, Fan Y, et al
    What drives the effectiveness of social distancing in combating COVID-19 across U.S. states?
    PLoS One. 2025;20:e0308244.
    PubMed         Abstract available
    
    
28. HASAN MB, Hossain MN, Khatun H, Uddin GS, et al
    Using smart transportation assets to hedge fossil energy markets: Evidence from quantile-based VAR approach.
    PLoS One. 2025;20:e0317748.
    PubMed         Abstract available
    
    
29. SOARES P, Gomez V, Gaio V, Santos JA, et al
    A protocol for high-dose quadrivalent influenza vaccine effectiveness in the community and long-term care facilities using electronic health records.
    PLoS One. 2025;20:e0314177.
    PubMed         Abstract available
    
    
30. DELGADO-ALONSO C, Matias-Guiu JA, Alvarado JM, Diez-Cirarda M, et al
    Computerized neuropsychological assessment in post-COVID condition.
    PLoS One. 2025;20:e0322304.
    PubMed         Abstract available
    
    
31. NOVELLI S, Reinkemeyer C, Bulaev D, O'Sullivan MP, et al
    Waning of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in 2020: A 12-month-evaluation in three population-based European studies.
    PLoS One. 2025;20:e0320196.
    PubMed         Abstract available
    
    
32. WANG H, Lu L, Liu Z, Sun Y, et al
    Study on measurement and prediction of agricultural product supply chain resilience based on improved EW-TOPSIS and GM (1,1)-Markov models under public emergencies.
    PLoS One. 2025;20:e0321248.
    PubMed         Abstract available
    
    
33. LUKASCHEK K, Hentschel H, Rottenkolber M, Alberer M, et al
    Association of mental health, quality of life, and SARS-CoV-2 infection in individuals in need of care: Results from a multicentre registry study.
    PLoS One. 2025;20:e0323017.
    PubMed         Abstract available
    
    
34. TURNER MM, Jang Y, Heo R, Ye Q, et al
    Mask wearing as a prosocial behavior: Proposing and testing the moral norms activation model.
    PLoS One. 2025;20:e0322921.
    PubMed         Abstract available
    
    
35. GIERTHMUEHLEN M, Gierthmuehlen PC
    COVIVA: Effect of transcutaneous auricular vagal nerve stimulation on fatigue-syndrome in patients with Long Covid - A placebo-controlled pilot study protocol.
    PLoS One. 2025;20:e0315606.
    PubMed         Abstract available
    
    

    
    Vaccine

36. FRANCIS MJ
    A rapid human vaccine process development map outlining lessons learnt from ChAdOx1 nCoV-19 vaccine during the COVID-19 pandemic.
    Vaccine. 2025;55:127040.
    PubMed         Abstract available
    
    
37. BLACKWELL CK, Bekelman T, Bakre S, Jacobson LP, et al
    Sociodemographic differences in parental hesitancy to the COVID-19 vaccine.
    Vaccine. 2025;55:127041.
    PubMed         Abstract available
    
    
38. FRIVOLD C, Giersing B, Amorij JP, Mvundura M, et al
    Identification of potential vaccines for use with microarray patches in low- and middle-income countries: An assessment from the Vaccine Innovation Prioritisation Strategy Alliance.
    Vaccine. 2025;55:126996.
    PubMed         Abstract available
    
    
39. GAGNON D, Gubany C, Ouakki M, Malo B, et al
    Factors influencing acceptance of RSV immunization for newborns among pregnant individuals: A mixed-methods study.
    Vaccine. 2025;55:127062.
    PubMed         Abstract available
    
    
40. TIRUNEH YM, Choi J, Cuccaro PM, Martinez J, et al
    Sociodemographic and health-related predictors of COVID-19 booster uptake among fully vaccinated adults.
    Vaccine. 2025;54:127048.
    PubMed         Abstract available
    
    
41. NEWBERN EC, Shoaibi A, Haynes K, Blacketer C, et al
    A rapid cycle analytics framework for vaccine safety surveillance within a real-world data network: Experience with enhanced surveillance of the Janssen COVID-19 vaccine.
    Vaccine. 2025;55:127044.
    PubMed         Abstract available
    
    
42. TILMANNE A, Pirson M, Leclercq P, Van Den Bulcke J, et al
    Evaluation of the costs of care for pediatric patients hospitalized for RSV: A retrospective cohort study in Belgium.
    Vaccine. 2025;55:127065.
    PubMed         Abstract available
    
    
43. CENAT JM, Moshirian Farahi SMM, Dalexis RD, Xu Y, et al
    Vaccine hesitancy among racially diverse parents in Canada: The important role of health literacy, conspiracy beliefs and racial discrimination.
    Vaccine. 2025;55:127049.
    PubMed         Abstract available
    
    
44. JIANG J, Lam KF, Lau EHY, Yin G, et al
    Estimation of trajectory of COVID-19 vaccines effectiveness against infection.
    Vaccine. 2025;55:127067.
    PubMed         Abstract available
    
    
45. PEREZ MARC G, Coria LM, Ceballos A, Rodriguez JM, et al
    Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial.
    Vaccine. 2025;54:127045.
    PubMed         Abstract available
    
    
46. ALVES K, Kouassi A, Plested JS, Kalkeri R, et al
    Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study.
    Vaccine. 2025;55:127046.
    PubMed         Abstract available
    
    
47. PAYNE AB, Novosad S, Sung HM, Zhang Y, et al
    Effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated hospitalizations among adults aged >/=18 years with end stage kidney disease - United States, September 2023-April 2024.
    Vaccine. 2025;55:127010.
    PubMed         Abstract available
    
    
48. PRALL S, Lopes A
    "Better to die trying": Vaccine perceptions and COVID-19 experiences in rural Namibian pastoralists.
    Vaccine. 2025;55:127061.
    PubMed         Abstract available
    
    
49. LA EM, Sweeney C, Davenport E, Bunniran S, et al
    Pharmacy and healthcare provider offices as convenient adult vaccination settings in the US: Patient experiences from a survey of recently-vaccinated adults.
    Vaccine. 2025;54:127057.
    PubMed         Abstract available
    
    
50. LEYNS C, McClenaghan E, Rodriguez P, Nguipdop-Djomo P, et al
    Hybrid, vaccine-induced and natural immunity against SARS-CoV-2 in traditional food markets in Bolivia (2020-2022): A cross-sectional analysis of a serological survey.
    Vaccine. 2025;54:127104.
    PubMed         Abstract available
    
    
51. ENTRICAN G, Bredell H, Charlier J, Cunningham AF, et al
    Opportunities and challenges for the adoption of novel platform technologies to develop veterinary bacterial vaccines.
    Vaccine. 2025;54:127117.
    PubMed         Abstract available
    
    
52. WEETS CM, Wilson R, Swadley H, Katz R, et al
    Strengthening health security through routine vaccination policy: A comprehensive analysis of childhood vaccination laws across 194 countries.
    Vaccine. 2025;54:127121.
    PubMed         Abstract available
    
    
53. STONER MCD, Michaels J, Stocks JB, Mancuso N, et al
    Evaluating concurrency and gaps between self-report and vaccine card data for COVID-19 vaccination.
    Vaccine. 2025;54:127136.
    PubMed         Abstract available
    
    
54. TAKEUCHI N, Chang B, Ishiwada N, Cho Y, et al
    Nationwide population-based surveillance of invasive pneumococcal disease in children in Japan (2014-2022): Impact of 13-valent pneumococcal conjugate vaccine and COVID-19 pandemic.
    Vaccine. 2025;54:127138.
    PubMed         Abstract available
    
    
55. CARTER DM, Bloom CE, Kirchenbaum GA, Tsvetnitsky V, et al
    Corrigendum to "Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine" [Vaccine (2015) 33(1) 108-16].
    Vaccine. 2025;57:127174.
    PubMed        
    
    
56. MOU J, LaSalle G, Pflugeisen C, Sherls-Jones J, et al
    Practice, beliefs and intent in influenza vaccination among Hispanic patients during the pandemic: An interventional study.
    Vaccine. 2025;58:127207.
    PubMed         Abstract available
    
    
57. XU J, Davoudpour S, Phillips G 2nd
    Applying the health belief model (HBM) to understand COVID-19 vaccine uptake among youth and young adults: Findings from a 6-month follow-up study in the United States.
    Vaccine. 2025;54:127002.
    PubMed         Abstract available
    
    
58. MYBURGH L, Karsjens H, Blanas A, de Ligt A, et al
    Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine.
    Vaccine. 2025;54:126989.
    PubMed         Abstract available
    
    
59. RICCI L, Fery C, Tubach F, Agrinier N, et al
    Health care institutions and their physicians are the greatest promoters of COVID-19 vaccine acceptance among health care workers.
    Vaccine. 2025;54:127005.
    PubMed         Abstract available
    
    
60. SKOCZYNSKA A, Golebiewska A, Wrobel-Pawelczyk I, Ronkiewicz P, et al
    The direct impact of mandatory PCV10 vaccination on invasive pneumococcal disease in Polish children.
    Vaccine. 2025;54:126999.
    PubMed         Abstract available
    
    
61. VEDEL JO, Furtado O, Almeida LL, Nehal KR, et al
    Childhood vaccination coverages in rural Guinea-Bissau before and during the early COVID-19 pandemic, a cohort study.
    Vaccine. 2025;54:127011.
    PubMed         Abstract available
    
    
62. DI CHIARA C, Karimi-Shahrbabak E, Peresin J, Farrar DS, et al
    A review of Canadian online resources providing information on COVID-19 vaccination for caregivers of children aged 5-11 years.
    Vaccine. 2025;54:126990.
    PubMed         Abstract available
    
    
63. FUJI N, Gonzalez E, Salamone FN, Bajorski P, et al
    Comparison of Streptococcus pneumoniae nasopharyngeal colonization, serotype-specific and protein-specific antibody and cytokine levels in young children prior to, during and post COVID-19 pandemic.
    Vaccine. 2025;54:126954.
    PubMed         Abstract available
    
    
64. DE SOUZA RA, Barreto FR, de Jesus Lima CCO, da Natividade MS, et al
    Efficacy of BCG vaccination on incidence, severity and clinical progression of COVID-19: A BCG-REVAC population analysis.
    Vaccine. 2025;54:126911.
    PubMed         Abstract available
    
    
65. DESILVA MB, Vazquez-Benitez G, Seburg EM, Henderson MSG, et al
    Pregnant persons perceptions and uptake of prenatal RSV vaccine - Minnesota, 2023-2024.
    Vaccine. 2025;54:126958.
    PubMed         Abstract available
    
    
66. DOWGIER G, Hobbs A, Greenwood D, Shawe-Taylor M, et al
    Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics.
    Vaccine. 2025;54:126960.
    PubMed         Abstract available
    
    
67. LEE DW, Nasir A, Elbashir S, Jani H, et al
    mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice.
    Vaccine. 2025;54:126961.
    PubMed         Abstract available
    
    
68. CARROLL M, Fox HB, Tran A, Chellappan G, et al
    SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect against evolving variants.
    Vaccine. 2025;54:126988.
    PubMed         Abstract available
    
    
69. MOORE M, Anderson L, Schiffer JT, Matrajt L, et al
    Durability of COVID-19 vaccine and infection induced immunity: A systematic review and meta-regression analysis.
    Vaccine. 2025;54:126966.
    PubMed         Abstract available
    
    
70. CHOI J, Feelemyer J, Choe K, Lynch K, et al
    Anti-vaccine attitudes and COVID-19 vaccine status at the end of the U.S. public health emergency.
    Vaccine. 2025;55:127003.
    PubMed         Abstract available
    
    
71. RASKIN N, Hiligsmann M, Luyten J, Tubeuf S, et al
    Socio-demographic differences in citizen' preferences for distributing a scarce, lifesaving resource: A case study using COVID-19 vaccine distribution in Belgium.
    Vaccine. 2025;55:126997.
    PubMed         Abstract available
    
    
72. HAO T, Ryan GE, Lydeamore MJ, Cromer D, et al
    Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19.
    Vaccine. 2025;55:126987.
    PubMed         Abstract available
    
    
73. HAMID S, Simeone RM, Newhams MM, Halasa N, et al
    Concordance between parent-reported and documented COVID-19 vaccination status among hospitalized children and adolescents: Implications for vaccine effectiveness estimates, May 2021-October 2023.
    Vaccine. 2025;54:126891.
    PubMed         Abstract available
    
    
74. KAISER S, Kaiser S, Reis J, Marschalek R, et al
    Quantification of objective concentrations of DNA impurities in mRNA vaccines.
    Vaccine. 2025;55:127022.
    PubMed         Abstract available
    
    
75. VACHON A, Keeshan A, Galipeau Y, Crawley AM, et al
    Alcohol consumption does not influence SARS-CoV-2 vaccine immunogenicity: A stop the spread Ottawa cohort analysis.
    Vaccine. 2025;55:127034.
    PubMed         Abstract available
    
    
76. GOLDMAN RD, Hart RJ, Bone JN, Seiler M, et al
    Adverse events among early caregivers' COVID-19 vaccination correlated inversely with intention to vaccinate their children.
    Vaccine. 2025;55:127001.
    PubMed         Abstract available
    
    

    
    Virology

77. LIU R, Song F, Sun L, Yan F, et al
    Exploring the pathogenic and transmission characteristics of JN.1 in golden hamsters based on different attack methods.
    Virology. 2025;608:110548.
    PubMed         Abstract available
    
    
78. CAO L, Shi S, Zhang C, Zhao C, et al
    A phycobiliprotein-based reporter assay for the evaluation of SARS-CoV-2 main protease activity.
    Virology. 2025;608:110540.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.